1. Cytoskeleton
    Cell Cycle/DNA Damage
    Antibody-drug Conjugate/ADC Related
  2. Microtubule/Tubulin
    ADC Cytotoxin

Monomethyl auristatin E (Synonyms: Vedotin; MMAE)

Cat. No.: HY-15162 Purity: 99.76%
Data Sheet SDS Handling Instructions

Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity.

For research use only. We do not sell to patients.
Monomethyl auristatin E Chemical Structure

Monomethyl auristatin E Chemical Structure

CAS No. : 474645-27-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO $332 In-stock
1 mg $90 In-stock
5 mg $210 In-stock
10 mg $310 In-stock
25 mg $690 In-stock
50 mg $960 In-stock
100 mg $1700 In-stock
200 mg $2650 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Monomethyl auristatin E:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity.

IC50 & Target

Microtubule[1]

In Vitro

Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].

In Vivo

Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02388490 Seoul National University Hospital|Seoul National University Bundang Hospital|SMG-SNU Boramae Medical Center Relapsed or Refractory EBV-and CD30-positive Lymphomas August 2015 Phase 2
NCT01940796 Massachusetts General Hospital|Seattle Genetics, Inc. Graft-vs-Host Disease|GVHD October 2013 Phase 1
NCT02164006 TG Therapeutics, Inc. Hodgkin's Lymphoma June 2014 Phase 1
NCT01900496 Sidney Kimmel Comprehensive Cancer Center Lymphoma April 2014 Early Phase 1
NCT02567851 University of Birmingham|Leukaemia Lymphoma Research|Millennium Pharmaceuticals, Inc. Hodgkin Disease February 2014 Phase 2
NCT02280785 Samsung Medical Center|Millennium Pharmaceuticals, Inc. Non-Hodgkin Lymphoma November 2014 Phase 2
NCT01851200 Fondazione Michelangelo|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Millennium Pharmaceuticals, Inc. Germ Cell Cancer May 2013 Phase 2
NCT03070990 Astellas Pharma Inc|Seattle Genetics, Inc. Metastatic Urothelial Cancer April 24, 2017 Phase 1
NCT01841021 H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Peripheral T-Cell Lymphoma April 2014
NCT01990534 Millennium Pharmaceuticals, Inc.|Takeda Hodgkin Lymphoma March 2014 Phase 4
NCT01492088 Millennium Pharmaceuticals, Inc.|Takeda Relapsed or Refractory Hodgkin Lymphoma|Relapsed or Refractory Anaplastic Large-cell Lymphoma April 16, 2012 Phase 1|Phase 2
NCT03007030 M.D. Anderson Cancer Center|Seattle Genetics, Inc. Lung Diseases Due to External Agents|Mesothelioma April 5, 2017 Phase 2
NCT01616680 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center Graft Versus Host Disease September 2012 Phase 2
NCT02939014 Takeda Hodgkin Disease|Lymphoma, Large-Cell, Anaplastic November 30, 2016 Phase 2
NCT03205891 M.D. Anderson Cancer Center|Takeda Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Classical Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|CD30+ Peripheral T-cell Lymphoma August 2017 Phase 1
NCT01671813 H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Lymphoma March 2013
NCT01807598 Jason Robert Gotlib|National Cancer Institute (NCI)|Stanford University Aggressive Systemic Mastocytosis|Mast Cell Leukemia|Systemic Mastocytosis September 2013 Phase 2
NCT02588651 Deepa Jagadeesh|Case Comprehensive Cancer Center T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepato-splenic T-cell Lymphoma|Adult T-cell Leukemia/Lymphoma|Enteropathy Associated T-cell Lymphoma|NK T-cell Lymphoma|Transformed Mycosis Fungoides June 2016 Phase 2
NCT01578499 Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma August 2012 Phase 3
NCT02497131 Fondazione Italiana Linfomi ONLUS Lymphatic Diseases September 2015 Phase 2
NCT02462538 Arbeitsgemeinschaft medikamentoese Tumortherapie ALK+ Anaplastic Large Cell Lymphoma May 2015 Phase 1|Phase 2
NCT02533570 Seattle Genetics, Inc. Systemic Lupus Erythematosus July 2015 Phase 2
NCT01393717 City of Hope Medical Center|National Cancer Institute (NCI) Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma October 20, 2011 Phase 2
NCT01596218 Massachusetts General Hospital|Seattle Genetics, Inc.|Dana-Farber Cancer Institute Graft vs. Host Disease July 2012 Phase 1
NCT02713828 PrECOG, LLC.|Celldex Therapeutics Squamous Cell Carcinoma of the Lung April 10, 2016 Phase 1|Phase 2
NCT01421667 Seattle Genetics, Inc. Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell August 2011 Phase 2
NCT02227433 Fondazione Italiana Linfomi ONLUS Hodgkin Lymphoma September 2014 Phase 2
NCT03219333 Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc Carcinoma, Transitional Cell|Urinary Bladder Neoplasms|Urologic Neoplasms|Renal Pelvis Neoplasms|Urothelial Cancer|Ureteral Neoplasms|Urethral Neoplasms September 2017 Phase 2
NCT03222492 National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Seattle Genetics, Inc. Diffuse Cutaneous Systemic Sclerosis|Scleroderma|dcSSc September 2017 Phase 1|Phase 2
NCT01909934 Millennium Pharmaceuticals, Inc.|Takeda Anaplastic Large-cell Lymphoma October 1, 2013 Phase 4
NCT02429375 Memorial Sloan Kettering Cancer Center|MethylGene Inc. Hodgkin Lymphoma April 2015 Phase 1|Phase 2
NCT02423291 Fondazione Italiana Linfomi ONLUS Primary Mediastinal Large B Cell Lymphoma October 2013 Phase 2
NCT01700751 Washington University School of Medicine Leukemia, Acute Myeloid|Leukemia, Lymphoblastic,Acute|Myelodysplastic Syndromes February 25, 2013 Phase 1
NCT01657331 Owen A. O'Connor|Columbia University Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma July 2012 Phase 1|Phase 2
NCT02244021 Fondazione Italiana Linfomi ONLUS Relapsed/Refractory Hodgkin's Lymphoma December 2014 Phase 2
NCT02581631 Bristol-Myers Squibb|Seattle Genetics, Inc. Non-Hodgkin's Disease December 18, 2015 Phase 1|Phase 2
NCT02254239 Mayo Clinic|National Cancer Institute (NCI) Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma February 4, 2016 Phase 1
NCT01396070 Youn Kim|Seattle Genetics, Inc.|Stanford University Non-Hodgkin Lymphoma (NHL)|Cutaneous Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides|Sezary Syndrome May 2011 Phase 2
NCT01805037 Northwestern University|Seattle Genetics, Inc. Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II G March 2013 Phase 1|Phase 2
NCT01703949 University of Washington|National Cancer Institute (NCI) CD30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma March 20, 2013
NCT03187210 University Hospital Inselspital, Berne|Mundipharma Medical Company Lymphoma July 2017 Phase 1|Phase 2
NCT02572167 Seattle Genetics, Inc.|Bristol-Myers Squibb Hodgkin Lymphoma October 2015 Phase 1|Phase 2
NCT01508312 Memorial Sloan Kettering Cancer Center|Seattle Genetics, Inc.|Hôpitaux Universitaires Henri Mondor, France Hodgkin's Lymphoma January 5, 2012 Phase 2
NCT01780662 National Cancer Institute (NCI) Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Refractory Childhood Hodgkin Lymphoma January 31, 2013 Phase 1|Phase 2
NCT01874054 Seattle Genetics, Inc. Hodgkin Disease June 2013 Phase 1|Phase 2
NCT02780011 The Methodist Hospital System|Millennium Pharmaceuticals, Inc. CD30-positive Lymphoma|CD30-positive Solid Tumor September 2016 Phase 1
NCT01461538 Seattle Genetics, Inc. Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia, Refractory, With Excess of Blasts|Solid Tumors October 2011 Phase 2
NCT02169505 M.D. Anderson Cancer Center Lymphoma May 22, 2015 Phase 2
NCT02487979 National Cancer Institute (NCI) Recurrent Osteosarcoma February 16, 2016 Phase 2
NCT01026233 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin January 2010 Phase 1
NCT02729961 University of Washington|National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma, ALK-Positive|Systemic Anaplastic Large Cell Lymphoma August 1, 2017 Phase 1|Phase 2
NCT02979522 Millennium Pharmaceuticals, Inc.|Takeda Hodgkin Disease July 18, 2017 Phase 1
NCT02096042 M.D. Anderson Cancer Center|Seattle Genetics, Inc. Leukemia April 2014 Phase 1|Phase 2
NCT02988843 Masonic Cancer Center, University of Minnesota Germ Cell Tumor March 29, 2017 Phase 2
NCT01950364 Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma|Anaplastic Large-cell Lymphoma November 2013 Phase 1
NCT02552121 Genmab Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer (NSCLC) October 2015 Phase 1|Phase 2
NCT02302339 Celldex Therapeutics Melanoma November 2014 Phase 2
NCT02616965 Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation Cutaneous T-cell Lymphoma (CTCL) February 22, 2017 Phase 1
NCT01992653 Genentech, Inc. Lymphoma, Non Hodgkin November 29, 2013 Phase 1|Phase 2
NCT02363283 National Cancer Institute (NCI) Recurrent Uveal Melanoma|Stage IV Uveal Melanoma September 16, 2015 Phase 2
NCT01620229 Fred Hutchinson Cancer Research Center|Seattle Genetics, Inc.|National Cancer Institute (NCI) Hematopoietic/Lymphoid Cancer June 2013 Phase 1|Phase 2
NCT01830777 Massachusetts General Hospital Acute Myelogenous Leukemia May 2013 Phase 1
NCT01902160 National Cancer Institute (NCI) Recurrent Adult Hodgkin Lymphoma September 2013 Phase 1
NCT02689219 Costantine Albany|Indiana University Germ Cell Tumors|Testis Cancer|Testicular Cancer|Embryonal Carcinoma|Nonseminomatous Germ Cell Tumor March 9, 2016 Phase 2
NCT02758717 Academic and Community Cancer Research United|National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Stage IB Hodgkin Lymphoma|Stage II Hodgkin Lymphoma|Stage IIA Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage III Hodgkin Lymphoma|Stage IIIA Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IV Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma May 2016 Phase 2
NCT03057795 City of Hope Medical Center|National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Hematopoietic Cell Transplantation Recipient|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma April 3, 2017 Phase 2
NCT01290549 Genentech, Inc. Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia March 22, 2011 Phase 1
NCT02086604 Washington University School of Medicine Lymphoma, Large B-Cell, Diffuse September 18, 2014 Phase 1
NCT02505269 Massachusetts General Hospital|Seattle Genetics, Inc. Hodgkin Lymphoma August 7, 2015 Phase 2
NCT02684292 Merck Sharp & Dohme Corp. Hodgkin Lymphoma May 23, 2016 Phase 3
NCT02298257 The Lymphoma Academic Research Organisation HIV Infection|HIV-associated Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma June 2015 Phase 2
NCT02744612 City of Hope Medical Center|National Cancer Institute (NCI)|Pharmacyclics LLC. Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma June 20, 2016 Phase 2
NCT02191930 University of Cologne Hodgkin Lymphoma September 2015 Phase 2
NCT02139592 Takeda Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma April 17, 2014
NCT01896999 National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma January 24, 2014 Phase 1|Phase 2
NCT01771107 National Cancer Institute (NCI) AIDS-Related Hodgkin Lymphoma|Classical Hodgkin Lymphoma|HIV Infection|Stage II Hodgkin Lymphoma|Stage IIA Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage III Hodgkin Lymphoma|Stage IIIA Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IV Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma March 7, 2013 Phase 1|Phase 2
NCT02001623 Genmab Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer(NSCLC)|Squamous Cell Carcinoma of the Head and Neck (SCCHN) November 2013 Phase 1|Phase 2
NCT03013933 City of Hope Medical Center|National Cancer Institute (NCI) Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|CD30-Positive Neoplastic Cells Present March 8, 2017 Phase 1
NCT02594163 Seattle Genetics, Inc. Diffuse Large B-cell Lymphoma Refractory|Follicular B-cell Non-Hodgkin's Lymphoma October 2015 Phase 2
NCT00866047 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin March 2009 Phase 2
NCT02275598 University of Modena and Reggio Emilia|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma April 2013 Phase 2
NCT01578967 UNC Lineberger Comprehensive Cancer Center|Seattle Genetics, Inc. Hodgkin Lymphoma, Adult April 2012
NCT02227199 University of Washington|National Cancer Institute (NCI) Recurrent Adult Hodgkin Lymphoma|Refractory Hodgkin Lymphoma October 10, 2014 Phase 1|Phase 2
NCT02280993 Marjolein Spiering|Millennium: The Takeda Oncology Company|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Hodgkin Lymphoma|Refractory|Relapse May 2014 Phase 1
NCT01196208 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Cutaneous
NCT01060904 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin January 2010 Phase 1
NCT01691898 Genentech, Inc. Follicular Lymphoma, Diffuse Large B-Cell Lymphoma September 26, 2012 Phase 1|Phase 2
NCT01100502 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin April 2010 Phase 3
NCT01994850 Abramson Cancer Center of the University of Pennsylvania CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma November 2013 Phase 1|Phase 2
NCT01026415 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Carcinomas|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Neoplasms December 2009 Phase 1
NCT02298283 The Lymphoma Academic Research Organisation Hodgkin Lymphoma April 2015 Phase 2
NCT02927769 Bristol-Myers Squibb Hodgkin Disease March 27, 2017 Phase 2
NCT01979536 National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma, ALK-Positive|CD30-Positive Neoplastic Cells Present|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma November 8, 2013 Phase 2
NCT01716806 Seattle Genetics, Inc.|Bristol-Myers Squibb Hodgkin Disease October 2012 Phase 2
NCT02822586 Virginia Commonwealth University|Seattle Genetics, Inc. Mycosis Fungoides|Sézary Syndrome December 19, 2016 Phase 1
NCT03198689 Lawson Health Research Institute|Seattle Genetics, Inc. Diffuse Cutaneous Systemic Sclerosis November 1, 2017 Phase 2
NCT00848926 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin February 2009 Phase 2
NCT02686346 The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. Hodgkin Disease March 2016 Phase 1|Phase 2
NCT01534078 Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Hodgkin Lymphoma March 2012 Phase 2
NCT02611323 Hoffmann-La Roche Non-Hodgkin's Lymphoma March 9, 2016 Phase 1
NCT02600897 Hoffmann-La Roche Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma March 23, 2016 Phase 1|Phase 2
NCT02734771 Patrick Reagan|Seattle Genetics, Inc.|University of Rochester Diffuse Large B-Cell Lymphoma June 2016 Phase 2
NCT01309789 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell February 2011 Phase 1
NCT03113500 City of Hope Medical Center|National Cancer Institute (NCI) Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|CD30-Positive Neoplastic Cells Present|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage III Anaplastic Large Cell Lymphoma|Stage IV Anaplastic Large Cell Lymphoma May 25, 2017 Phase 2
NCT00947856 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin July 2009 Phase 2
NCT03217643 Imagine Institute Enteropathy Associated T-cell Lymphoma September 2017 Phase 2
NCT03138499 Bristol-Myers Squibb Hodgkin's Disease May 16, 2017 Phase 3
NCT02292979 The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma March 2015 Phase 2
NCT01777152 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma January 2013 Phase 3
NCT03067935 Celldex Therapeutics Metastatic gpNMB Expressing Triple Negative Breast Cancer
NCT02166463 National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma March 16, 2015 Phase 3
NCT02257567 Hoffmann-La Roche Lymphoma October 14, 2014 Phase 1|Phase 2
NCT01925612 Seattle Genetics, Inc. Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse August 2013 Phase 2
NCT02243436 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Millennium Pharmaceuticals, Inc. CLASSICAL HODGKIN LYMPHOMA November 2014 Phase 1|Phase 2
NCT01868451 Memorial Sloan Kettering Cancer Center|Seattle Genetics, Inc.|University of Rochester|City of Hope Medical Center|Stanford University Hodgkin Lymphoma May 2013
NCT02729896 Hoffmann-La Roche Lymphoma November 9, 2016 Phase 1
NCT01920932 St. Jude Children's Research Hospital|Seattle Genetics, Inc. Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma August 12, 2013 Phase 2
NCT02499627 Fondazione Italiana Linfomi ONLUS Lymphatic Diseases October 2015 Phase 2
NCT01476410 Northwestern University|Robert H. Lurie Cancer Center|Seattle Genetics, Inc. Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma November 2011 Phase 2
NCT02098512 New York Medical College|St. Baldrick's Foundation Hodgkin Lymphoma March 2014 Phase 1|Phase 2
NCT01712490 Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda Hodgkin Lymphoma November 2012 Phase 3
NCT02398240 Mitchell Cairo|New York Medical College Hodgkin Lymphoma May 2015 Phase 2
NCT02408042 Western Regional Medical Center Lymphoma|Hodgkin's Lymphoma|Non-hodgkin's Lymphoma April 2015 Phase 1|Phase 2
NCT01569204 University of Cologne Hodgkin Lymphoma October 2012 Phase 2
NCT02661503 University of Cologne Classical Hodgkin Lymphoma July 2016 Phase 3
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.3928 mL 6.9640 mL 13.9280 mL
5 mM 0.2786 mL 1.3928 mL 2.7856 mL
10 mM 0.1393 mL 0.6964 mL 1.3928 mL
Cell Assay
[2]

Monomethyl auristatin E is reconstituted in DMSO.

Monomethyl auristatin E (MMAE, 5 nM) and ionizing radiation (IR) treated cells are harvested and lysed in RIPA buffer with protease and phosphatase inhibitors. Thirty μg of lysate undergo electrophoresis using 4-12% Bis-Tris gels, transferred to PVDF membranes and incubated with indicated primary antibodies. Blots are developed by ECL. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice[2]
6-8 week old female athymic nu/nu mice are injected subcutaneously into thighs with 5×106 HCT-116 or PANC-1 cells in a 1:1 Matrigel and PBS solution. Mice are treated with IR or intravenous (IV) injection of ACPP-cRGD-MMAE (6 nmoles/day, 18 nmoles total, i.v.), tumor tissue is harvested, formalin fixed and paraffin embedded followed by staining with indicated antibodies. The primary antibody is used at a 1:250 dilution and is visualized using DAB as a chromagen with the UltraMap system. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
M.Wt

717.98

Formula

C₃₉H₆₇N₅O₇

CAS No.

474645-27-7

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 48 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.76%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Monomethyl auristatin E
Cat. No.:
HY-15162
Quantity: